67346-60-5

Basic information

• Product Name: (R)-(-)-1-(4'-methoxyphenyl)-2-benzylaminopropane
• Synonyms: (R)-(-)-1-(4'-methoxyphenyl)-2-benzylaminopropane;(R)-N-benzyl-1-(4-methoxyphenyl)propan-2-amine
• CAS NO: 67346-60-5
• Molecular Formula: C₁₇H₂₁NO
• Molecular Weight: 255.35474
• Mol File: 67346-60-5.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 377.8±22.0 °C(Predicted)
• Appearance: /
• Density: 1.024±0.06 g/cm3(Predicted)
• PKA: 9.54±0.19(Predicted)
• CAS DataBase Reference: (R)-(-)-1-(4'-methoxyphenyl)-2-benzylaminopropane(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(-)-1-(4'-methoxyphenyl)-2-benzylaminopropane(67346-60-5)
• EPA Substance Registry System: (R)-(-)-1-(4'-methoxyphenyl)-2-benzylaminopropane(67346-60-5)

Safety Data

• Hazardous Substances Data: 67346-60-5(Hazardous Substances Data)

Usage

Description

(R)-(-)-1-(4'-methoxyphenyl)-2-benzylaminopropane, also known as the R enantiomer of 1-(4-Methoxyphenyl)-2-(benzylamino)propane (M260970), is an essential intermediate in the synthesis of Formoterol Fumarate (F693401). (R)-(-)-1-(4'-methoxyphenyl)-2-benzylaminopropane plays a crucial role in the pharmaceutical industry due to its involvement in the production of a significant medication.

Uses

Used in Pharmaceutical Industry:
(R)-(-)-1-(4'-methoxyphenyl)-2-benzylaminopropane is used as a key intermediate in the synthesis of Formoterol Fumarate (F693401) for its role in creating a medication that serves various therapeutic purposes. Formoterol Fumarate is a long-acting beta-2 adrenergic agonist (LABA) used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). It helps to relax the muscles in the airways and improve breathing for patients suffering from these respiratory conditions.

Upstream product

• 122-84-9 4-methoxybenzyl methyl ketone 
• 100-46-9 benzylamine 
• 245759-64-2 (R)-N-benzyl-N-(1-methyl-2-p-methoxyphenylethyl)amine L-mandelate 
• 43229-65-8 [2-(4-methoxyphenyl)-1-methylethyl](phenylmethyl)amine 
• 1096141-37-5 C₁₇H₁₉NO 
• 17199-29-0 (S)-Mandelic acid 
• 104-01-8 4-Methoxyphenylacetic acid 
• 245759-64-2 N-benzyl-1-(4-methoxyphenyl)propan-2-amine mandalate salt 
• 1049695-95-5 benzyl-[2-(4-methoxy-phenyl)-1-methyl-ethyl]-amine; hydrochloride 
• 58993-79-6 (R)-(-)-p-methoxyamphetamine 
• 100-52-7 benzaldehyde 

Downstream Products

• 245759-65-3 (R,R)-3-nitro-α-[[[2-(4-methoxyphenyl)-1-methylethyl](phenylmethyl)amino]methyl]-4-(phenylmethoxy)-benzenemethanol 
• 1026431-67-3 C₃₉H₄₁NO₄ 
• 67346-50-3 (S,R)-Formoterol 
• 73573-87-2 (R,R)-formoterol 
• 289657-26-7 (R,R)-3-amino-α-[[[2-(4-methoxyphenyl)-1-methylethyl](phenyl methyl)amino]methyl]-4-(phenylmethoxy)-benzenemethanol 
• 289657-25-6 (S)-1-(3-Amino-4-benzyloxy-phenyl)-2-{benzyl-[(R)-2-(4-methoxy-phenyl)-1-methyl-ethyl]-amino}-ethanol 
• 188690-83-7 N-[5-[(1R)-Hydroxy-2-[[(1R)-methyl-2-(4-methoxyphenyl)ethyl](phenylmethyl)amino]ethyl]-2-(phenylmethoxy)phenyl]-formamide 
• 1042738-15-7 5-[[[(1R)-2-(4-methoxyphenyl)-1-methylethyl](phenylmethyl)amino]acetyl]-8-(phenylmethoxy)-(1H)-quinolin-2-one monohydrochloride 
• 1122063-39-1 4-(2-(benzylamino)propyl)phenol 
• 1198769-18-4 (R)-4-benzyloxy-3-nitro-α-(N-benzyl-N-(1-methyl-2-p-methoxyphenylethyl)amino)acetophenone 

Relevant articles and documents

Direct Reductive Amination of Carbonyl Compounds with H2 Using Heterogeneous Catalysts in Continuous Flow as an Alternative to N-Alkylation with Alkyl Halides

A general continuous-flow procedure for direct reductive amination of secondary and primary amines with aromatic and aliphatic aldehydes as well as ketones is reported. The use of hydrogen gas and commercially available Pt/C as a heterogeneous catalyst is a key. In addition to exhibiting an excellent functional group tolerance, this method allows the fast formation of C?N bonds without production of any hazardous chemical waste. Applications to the synthesis of key intermediates toward active pharmaceutical ingredients (Donepezil and Arformoterol/Tamsulosin) are also described. (Figure presented.).

Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas

This disclosure concerns the discovery of the use of fenoterol and (R,R)- and (R,S)-fenoterol analogs for the treatment of a tumor expressing a β2-adrenergic receptor, such as a primary brain tumor, including a glioblastoma or astrocytoma expressing a β2-adrenergic receptor. In one example, the method includes administering to a subject a therapeutically effective amount of fenoterol, a specific fenoterol analog or a combination thereof to reduce one or more symptoms associated with the tumor, thereby treating the tumor in the subject.

Direct Asymmetric Reductive Amination for the Synthesis of Chiral β-Arylamines

The highly efficient and direct asymmetric reductive amination of arylacetones catalyzed by an iridium complex for the preparation of enantiomerically pure β-arylamines is described. The monodentate phosphoramidite ligand exhibits superb reactivity (TONs of up to 20 000) and enantioselectivity (up to 99 % ee). Additives played important roles in this reductive coupling reaction. Asymmetric reductive coupling of a ketone and an amine is a straightforward and atom-economic approach for preparing optically enriched amines. The highly efficient and direct asymmetric reductive amination of arylacetones, catalyzed by an iridium complex, supplies enantiomerically pure β-arylamines. The new phosphoramidite ligands reported show superb reactivity and enantioselectivity in this reductive coupling. M.S.=molecular sieves, TFA=trifluoroacetic acid.